MedTrace Logo

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-03-13

No results posted yet for this study

Summary

This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.

Conditions

Interventions

DRUG

Daclizumab

1mg/kg medication every other week on the odd week (week 1-13).

DRUG

Cyclosporine

2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.

DRUG

cyclosporine and Daclizumab

1mg/kg plus low dose cyclosporine (2 mg/kg/day)

Sponsors & Collaborators

  • Facet Biotech

    collaborator INDUSTRY

  • Rockefeller University

    lead OTHER

Principal Investigators

  • James Krueger, MD, PHD · Rockefeller University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-10-31
Primary Completion
2004-09-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050648 on ClinicalTrials.gov